YDES:NASDAQYD Bio Limited Analysis
Data as of 2026-09-01 - not real-time
$3.78
Latest Price
9/10Risk
Risk Level: High
Executive Summary
YD Bio Ltd trades at $3.77, with its moving averages tangled rather than clearly stacked — a neutral trend structure. The last 30 days have gained 66.3%. With RSI at 53.2 the momentum picture is neutral, alongside a bearish MACD signal. Watch $2.17 as support and $5.00 as the nearer resistance level.
Revenue is growing at 95.6% on a -276.6% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 149.8%, a beta of 0.69 and a maximum drawdown of 91.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Revenue is growing at 95.6% on a -276.6% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 149.8%, a beta of 0.69 and a maximum drawdown of 91.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
Taipei, Taiwan, July 02, 2026 GLOBE NEWSWIRE -- YD Bio Limited 'YD Bio” or the 'Company” Nasdaq: YDES , a...Taipei, Taiwan, July 02, 2026 GLOBE NEWSWIRE -- YD Bio Limited "YD Bio" or the "Company" Nasdaq: YDES , a biotechnology...Yahoo Finance1monYD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 6.89
- MACD momentum is negative
- 30-day price change of +66.3%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 6.89
- 30-day volatility of 149.8%
- MACD momentum is negative
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -276.6%
- Negative return on equity of -42.7%
- Revenue growth of +95.6%
Key Metrics & Analysis
Financial Health
Revenue Growth95.60%
Profit Margin-276.58%
ROE-42.69%
ROA-25.43%
Debt/Equity0.34
P/B Ratio0.8
Op. Cash Flow$-1836818
Free Cash Flow$-3875569
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI53.2
Support$2.17
Resistance$5.00
MA 20$3.57
MA 50$2.78
MA 200$6.89
MACDBearish
VolumeIncreasing
Fear & Greed Index92.25
Valuation
GradeFair
TypeBlend
Risk Assessment
Beta0.69
Volatility149.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.